Research programme: nitric oxide synthase type II inhibitors - Adolor Corporation

Drug Profile

Research programme: nitric oxide synthase type II inhibitors - Adolor Corporation

Alternative Names: BBS-2; iNOS dimerisation inhibitors - Adolor Corporation; iNOS inhibitors - Adolor Corporation

Latest Information Update: 11 Mar 2009

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class
  • Mechanism of Action Immunosuppressants; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Neuropathic pain
  • Discontinued Autoimmune disorders

Most Recent Events

  • 07 Sep 2007 Preclinical trials in Inflammation in USA (unspecified route)
  • 07 Sep 2007 Preclinical trials in Neuropathic pain in USA (unspecified route)
  • 07 Sep 2007 Preclinical trials in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top